Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Antipsychotic Treatment”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT01760993
What this trial is testing

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Who this might be right for
Schizophrenia
Shire 2
Post-approval studies (Phase 4)Study completedNCT00981526
What this trial is testing

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

Who this might be right for
SchizophreniaSchizoaffective Disorder
University of Massachusetts, Worcester 66
Post-approval studies (Phase 4)Study completedNCT00495352
What this trial is testing

The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia

Who this might be right for
Tobacco DependenceSchizophrenia
Yu-Li Hospital 360
Not applicableNot Yet RecruitingNCT07805980
What this trial is testing

A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia

Who this might be right for
SchizophreniaAntipsychotic Induced Weight Gain
Second Xiangya Hospital of Central South University 30
Post-approval studies (Phase 4)UnknownNCT03883204
What this trial is testing

Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up

Who this might be right for
SchizophreniaPsychotic DisordersPsychosis
Fundación Marques de Valdecilla 115
Not applicableActive Not RecruitingNCT07351240
What this trial is testing

The Acupuncture Treatment Effect in Patients With Schizophrenia

Who this might be right for
Mental Health
Calo Psychiatric Center 100
Post-approval studies (Phase 4)Study completedNCT00000374
What this trial is testing

Treatment for First-Episode Schizophrenia

Who this might be right for
Schizophrenia
Northwell Health 125
Large-scale testing (Phase 3)Study completedNCT01281527
What this trial is testing

Paliperidone Palmitate Flexible Dosing in Schizophrenia

Who this might be right for
Schizophrenia
Janssen-Cilag International NV 1,044
Large-scale testing (Phase 3)Study completedNCT00253162
What this trial is testing

The Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol

Who this might be right for
Bipolar DisordersManic Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 439
Post-approval studies (Phase 4)UnknownNCT01016145
What this trial is testing

Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm

Who this might be right for
Schizophrenia or Schizoaffective Disorder
University of Sao Paulo 126
Not applicableLooking for participantsNCT06756139
What this trial is testing

Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia

Who this might be right for
Functional DyspepsiaSelf-help Mobile Cognitive Behavioral TherapyAntipsychotic Drug
Air Force Military Medical University, China 88
Not applicableUnknownNCT04784572
What this trial is testing

Assessment of Pain During Intramuscular Injection Delay in Adult Psychiatry

Who this might be right for
Delayed Antipsychotic Treatment, Pharmacological Factors and Individual Factors
Centre hospitalier de Ville-Evrard, France 393
Testing effectiveness (Phase 2)Study completedNCT00709345
What this trial is testing

Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks

Who this might be right for
Mental Illness
Medical College of Wisconsin 333
Large-scale testing (Phase 3)Study completedNCT02431702
What this trial is testing

Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Who this might be right for
SchizophreniaPsychotic Disorders
Janssen Scientific Affairs, LLC 337
Testing effectiveness (Phase 2)Study completedNCT00401089
What this trial is testing

Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia

Who this might be right for
SchizophreniaSchizoaffective DisorderTardive Dyskinesia+2 more
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 60
Testing effectiveness (Phase 2)Study completedNCT00628290
What this trial is testing

Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis

Who this might be right for
Schizophrenia
University of Cologne 42
Not applicableStudy completedNCT00873249
What this trial is testing

Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia

Who this might be right for
Schizophrenia
AstraZeneca 339
Post-approval studies (Phase 4)Looking for participantsNCT04373317
What this trial is testing

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

Who this might be right for
Parkinson's Disease Psychosis
VA Office of Research and Development 358
Not applicableStudy completedNCT00230893
What this trial is testing

Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years

Who this might be right for
PTSDPost-Traumatic Stress Disorder
Tuscaloosa Research & Education Advancement Corporation 99
Post-approval studies (Phase 4)Ended earlyNCT00934635
What this trial is testing

A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls

Who this might be right for
Schizophrenia
Janssen-Cilag G.m.b.H 2
Next Page